Medical Oncology

, Volume 27, Issue 3, pp 899–906

Efficacy and safety of sorafenib in patients with advanced renal cell carcinoma with and without prior cytokine therapy, a subanalysis of TARGET

  • S. Negrier
  • E. Jäger
  • C. Porta
  • D. McDermott
  • M. Moore
  • J. Bellmunt
  • S. Anderson
  • F. Cihon
  • J. Lewis
  • B. Escudier
  • R. Bukowski
Original Paper


Before the development of targeted therapies, administration of cytokines (e.g., interleukin-2, interferon-α) was the primary systemic treatment option for advanced renal cell carcinoma. Sorafenib, an oral targeted, multikinase inhibitor, significantly prolonged progression-free survival and overall survival in the Treatment Approaches in Renal Cancer Global Evaluation Trial (TARGET), a large (N = 903) phase III, double-blind, randomised, placebo-controlled study of patients with advanced renal cell carcinoma resistant to standard therapy. This analysis of a patient subgroup from TARGET evaluated the safety and efficacy of sorafenib in patients who had received prior cytokine therapy (sorafenib: n = 374; placebo: n = 368) and in patients who were cytokine-naïve (sorafenib: n = 77; placebo: n = 84). Progression-free survival was significantly prolonged with sorafenib therapy compared with placebo among patients with and without prior cytokine therapy (respectively 5.5 vs. 2.7 months; hazard ratio, 0.54; 95% confidence interval, 0.45–0.64 and 5.8 vs. 2.8 months; hazard ratio, 0.48; 95% confidence interval, 0.32–0.73). Clinical benefit rates for sorafenib-treated patients compared with placebo patients were also higher (cytokine-treated: 83 vs. 54.3%; cytokine-naïve: 85.7 vs. 56.0%). Sorafenib was well tolerated in both subgroups (grade 3/4: 20 and 22%, respectively). Sorafenib demonstrated a consistent, significant clinical benefit against advanced renal cell carcinoma, with a twofold improvement in progression-free survival and disease control rate, with similar toxicities in patients with or without prior cytokine treatment.


Sorafenib Cytokine Interferon Interleukin Renal cell cancer Multikinase inhibitor Subanalysis 


  1. 1.
    Reuter VE, Presti JC Jr. Contemporary approach to the classification of renal epithelial tumors. Semin Oncol. 2000;27(2):124–37.PubMedGoogle Scholar
  2. 2.
    National Cancer Institute. Cancer topics: kidney cancer. 13 April 2009.
  3. 3.
    McLaughlin JK, Lipworth L, Tarone RE. Epidemiologic aspects of renal cell carcinoma. Semin Oncol. 2006;33(5):527–33.CrossRefPubMedGoogle Scholar
  4. 4.
    Scelo G, Brennan P. The epidemiology of bladder and kidney cancer. Nat Clin Pract Urol. 2007;4(4):205–17.CrossRefPubMedGoogle Scholar
  5. 5.
    Vogelzang NJ, Stadler WM. Kidney cancer. Lancet. 1998;352(9141):1691–6.CrossRefPubMedGoogle Scholar
  6. 6.
    Milowsky MI, Nanus DM. Advanced renal cell carcinoma. Curr Treat Options Oncol. 2001;2(5):437–45.CrossRefPubMedGoogle Scholar
  7. 7.
    Schoffski P, Dumez H, Clement P, et al. Emerging role of tyrosine kinase inhibitors in the treatment of advanced renal cell cancer: a review. Ann Oncol. 2006;17(8):1185–96.CrossRefPubMedGoogle Scholar
  8. 8.
    Fyfe GA, Fisher RI, Rosenberg SA, et al. Long-term response data for 255 patients with metastatic renal cell carcinoma treated with high-dose recombinant interleukin-2 therapy. J Clin Oncol. 1996;14(8):2410–1.PubMedGoogle Scholar
  9. 9.
    Negrier S, Escudier B, Lasset C, et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d’Immunotherapie. N Engl J Med. 1998;338(18):1272–8.CrossRefPubMedGoogle Scholar
  10. 10.
    Gnarra JR, Tory K, Weng Y, et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet. 1994;7(1):85–90.CrossRefPubMedGoogle Scholar
  11. 11.
    Maxwell PH, Wiesener MS, Chang GW, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 1999;399(6733):271–5.CrossRefPubMedGoogle Scholar
  12. 12.
    Sowter HM, Raval RR, Moore JW, Ratcliffe PJ, Harris AL. Predominant role of hypoxia-inducible transcription factor (Hif)-1alpha versus Hif-2alpha in regulation of the transcriptional response to hypoxia. Cancer Res. 2003;63(19):6130–4.PubMedGoogle Scholar
  13. 13.
    Ahmad T, Eisen T. Kinase inhibition with BAY 43–9006 in renal cell carcinoma. Clin Cancer Res. 2004;10(18 Pt 2):6388S–92S.CrossRefPubMedGoogle Scholar
  14. 14.
    Wilhelm SM, Adnane L, Newell P, et al. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther. 2008;7(10):3129–40.CrossRefPubMedGoogle Scholar
  15. 15.
    Lierman E, Folens C, Stover EH, et al. Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant. Blood. 2006;108(4):1374–6.CrossRefPubMedGoogle Scholar
  16. 16.
    Wilhelm SM, Carter C, Tang L, et al. BAY 43–9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004;64(19):7099–109.CrossRefPubMedGoogle Scholar
  17. 17.
    Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356(2):125–34.CrossRefPubMedGoogle Scholar
  18. 18.
    Escudier B, Eisen T, Stadler WM, et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 2009 (Epub ahead of print).Google Scholar
  19. 19.
    Motzer RJ, Mazumdar M, Bacik J, et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999;17(8):2530–40.PubMedGoogle Scholar
  20. 20.
    Nexavar (sorafenib) prescribing information. Bayer Pharmaceuticals; 2008.Google Scholar
  21. 21.
    Coppin C, Porzsolt F, Awa A, et al. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev. 2005;1:CD001425.PubMedGoogle Scholar
  22. 22.
    Ramsey S, Aitchison M. Treatment for renal cancer: are we beyond the cytokine era? Nat Clin Pract Urol. 2006;3(9):478–84.CrossRefPubMedGoogle Scholar
  23. 23.
    Fyfe G, Fisher RI, Rosenberg SA, et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol. 1995;13(3):688–96.PubMedGoogle Scholar
  24. 24.
    Negrier S, Escudier B, Gomez F, et al. Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Francais d’Immunotherapie. Ann Oncol. 2002;13(9):1460–8.CrossRefPubMedGoogle Scholar
  25. 25.
    Tourani JM, Pfister C, Tubiana N, et al. Subcutaneous interleukin-2 and interferon alfa administration in patients with metastatic renal cell carcinoma: final results of SCAPP III, a large, multicenter, phase II, nonrandomized study with sequential analysis design–the Subcutaneous Administration Propeukin Program Cooperative Group. J Clin Oncol. 2003;21(21):3987–94.CrossRefPubMedGoogle Scholar
  26. 26.
    Escudier B, Chevreau C, Lasset C, et al. Cytokines in metastatic renal cell carcinoma: is it useful to switch to interleukin-2 or interferon after failure of a first treatment? Groupe Francais d’Immunotherape. J Clin Oncol. 1999;17(7):2039–43.PubMedGoogle Scholar
  27. 27.
    Motzer RJ, Mazumdar M, Bacik J, et al. Effect of cytokine therapy on survival for patients with advanced renal cell carcinoma. J Clin Oncol. 2000;18(9):1928–35.PubMedGoogle Scholar
  28. 28.
    Gleave ME, Elhilali M, Fradet Y, et al. Interferon gamma-1b compared with placebo in metastátic renal-cell carcinoma. N Engl J Med. 1998;338(18):1265–71.CrossRefPubMedGoogle Scholar
  29. 29.
    Gollob JA, Rathmell WK, Richmond TM, et al. Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell carcinoma. J Clin Oncol. 2007;25(22):3288–95.CrossRefPubMedGoogle Scholar
  30. 30.
    Ryan CW, Goldman BH, Lara PN, et al. Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group. J Clin Oncol. 2007;25(22):3296–301.CrossRefPubMedGoogle Scholar
  31. 31.
    Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N Engl J Med. 1996;335(12):865–75.CrossRefPubMedGoogle Scholar

Copyright information

© Humana Press Inc. 2009

Authors and Affiliations

  • S. Negrier
    • 1
  • E. Jäger
    • 2
  • C. Porta
    • 3
  • D. McDermott
    • 4
  • M. Moore
    • 5
  • J. Bellmunt
    • 6
  • S. Anderson
    • 7
  • F. Cihon
    • 7
  • J. Lewis
    • 7
  • B. Escudier
    • 8
  • R. Bukowski
    • 9
  1. 1.Centre Leon Berard and Claude Bernard UniversityLyonFrance
  2. 2.Krankenhaus NordwestFrankfurtGermany
  3. 3.IRCCS San Matteo University Hospital FoundationPaviaItaly
  4. 4.Beth Israel Deaconess Medical CenterBostonUSA
  5. 5.Princess Margaret HospitalTorontoCanada
  6. 6.University Hospital del MarBarcelonaSpain
  7. 7.Bayer PharmaceuticalsWest HavenUSA
  8. 8.Institut Gustave RoussyVillejuifFrance
  9. 9.Cleveland Clinic Cancer CenterClevelandUSA

Personalised recommendations